Chunguang Xie, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Tirzepatide is a 39amino acid dual incretin receptor agonist that activates both GLP1 and GIP receptors, enhancing glucosedependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [1] [2]
In mice models, there was a reduction in hyperglycemia, weight loss and increased energy expenditure compared to liraglutide [68,69]
BPC-157 has been studied extensively in in vitro and preclinical models in the context of regenerative biology
With that information, you can decide whether GLP-1 probiotics are worth your timeor whether more proven, evidence-based strategies may be a better fit for your goals